Record Johnson and Johnson Baby Powder Verdict of 1.5 Billion Dollars Shocks Pharma World
Nikhilk Prasad Fact checked by:Thailand Medical News Team Jan 03, 2026 1 day, 20 minutes ago
Pharma News: Baltimore Jury Delivers Staggering Award
In a landmark ruling that could send ripples through the pharmaceutical and consumer products industries, a Baltimore City jury has ordered Johnson & Johnson and its corporate affiliates to pay over US$1.5 billion to a Maryland woman who says years of using the company’s talc-based baby powder caused her to develop a rare asbestos-related cancer. This
Pharma News report underscores the significance of the verdict, which legal experts are calling the largest ever won by a single talc plaintiff against the healthcare giant.
Massive verdict in Baltimore orders J&J to pay over US$1.5 billion after talc cancer claim
The decision came on December 22, 2025, in the Circuit Court for Baltimore City, where jurors found that Johnson & Johnson, two of its subsidiaries, and its consumer health spinoff Kenvue failed to warn consumers that their talc-based products contained asbestos — a known carcinogen linked to peritoneal mesothelioma, a deadly cancer of the abdomen lining. Peritoneal mesothelioma most often arises decades after exposure to asbestos, and unlike many other cancers, it remains difficult to treat.
Who Is the Plaintiff and What Evidence Was Presented
The plaintiff, Cherie A. Craft, a nonprofit leader and lifelong user of J&J’s baby powder products, testified that she used the powders daily for much of her life. In January 2024 she was diagnosed with malignant peritoneal mesothelioma, a rare cancer strongly associated with asbestos exposure. Evidence presented at trial included decades of internal documents and expert testimony suggesting asbestos contamination in talc products and repeated corporate failures to disclose risks to consumers.
The jury’s award breakdown revealed $59.84 million in compensatory damages to cover Craft’s medical costs, pain and suffering, and lost wages, along with $1 billion in punitive damages against Johnson & Johnson and $500 million against Pecos River Talc LLC, a J&J subsidiary. Punitive damages are intended to punish particularly reckless conduct and deter similar corporate behavior in the future.
Corporate Response and Legal Fallout
Johnson & Johnson wasted no time vowing to appeal the verdict, characterizing the decision as “egregious and patently unconstitutional,” and asserting that the science linking their talc products to cancer is flawed. The company continues to insist that their talc-based powders were safe and free of asbestos, referencing decades of studies, and notes that it removed talc products from the market globally by 2023.
Despite J&J’s defense, the verdict comes amid a surge of talc litigation across the U.S., where tens of thousands of claims are pending. Prior attempts by J&J to settle these claims through bankruptcy proceedings have failed, leaving many cases poised to proceed in trial courts. Other juries have handed down significant awards in recent months, inc
luding a separate California trial awarding $40 million in an ovarian cancer case.
Impact on Consumers and the Legal Landscape
Mesothelioma caused by asbestos exposure is incurable, and treatments like surgery and chemotherapy typically focus on symptom management rather than cure. The verdict highlights ongoing public concern about long-term exposure to seemingly benign consumer products. Legal analysts say the Baltimore decision could embolden other plaintiffs and further strain Johnson & Johnson’s litigation strategy, especially as juries increasingly find evidence of asbestos contamination compelling.
This record-setting award sends a potent message about corporate accountability and consumer safety, raising questions about past product oversight and informing future litigation trends in talc-related cancer cases.
For the latest
Pharma News, keep on logging to Thailand Medical News
Read Also:
https://www.thailandmedical.news/articles/pharma-news
Share
Tweet
Share
